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Summary
Background Choroideremia is an X-linked recessive disease that leads to blindness due to mutations in the CHM 
gene, which encodes the Rab escort protein 1 (REP1). We assessed the eﬀ ects of retinal gene therapy with an adeno-
associated viral (AAV) vector encoding REP1 (AAV.REP1) in patients with this disease.
Methods In a multicentre clinical trial, six male patients (aged 35–63 years) with choroideremia were administered 
AAV.REP1 (0·6–1·0 × 10¹⁰ genome particles, subfoveal injection). Visual function tests included best corrected visual 
acuity, microperimetry, and retinal sensitivity tests for comparison of baseline values with 6 months after surgery. 
This study is registered with ClinicalTrials.gov, number NCT01461213.
Findings Despite undergoing retinal detachment, which normally reduces vision, two patients with advanced 
choroideremia who had low baseline best corrected visual acuity gained 21 letters and 11 letters (more than two and 
four lines of vision). Four other patients with near normal best corrected visual acuity at baseline recovered to within 
one to three letters. Mean gain in visual acuity overall was 3·8 letters (SE 4·1). Maximal sensitivity measured with 
dark-adapted microperimetry increased in the treated eyes from 23·0 dB (SE 1·1) at baseline to 25·3 dB (1·3) after 
treatment (increase 2·3 dB [95% CI 0·8–3·8]). In all patients, over the 6 months, the increase in retinal sensitivity in 
the treated eyes (mean 1·7 [SE 1·0]) was correlated with the vector dose administered per mm² of surviving retina 
(r=0·82, p=0·04). By contrast, small non-signiﬁ cant reductions (p>0·05) were noted in the control eyes in both 
maximal sensitivity (–0·8 dB [1·5]) and mean sensitivity (–1·6 dB [0·9]). One patient in whom the vector was not 
administered to the fovea re-established variable eccentric ﬁ xation that included the ectopic island of surviving retinal 
pigment epithelium that had been exposed to vector.
Interpretation The initial results of this retinal gene therapy trial are consistent with improved rod and cone function 
that overcome any negative eﬀ ects of retinal detachment. These ﬁ ndings lend support to further assessment of gene 
therapy in the treatment of choroideremia and other diseases, such as age-related macular degeneration, for which 
intervention should ideally be applied before the onset of retinal thinning.
Funding UK Department of Health and Wellcome Trust.
Introduction
Choroideremia (OMIM 303100) is currently an incurable 
X-linked recessive degenerative disease of the retina and 
choroid that might ﬁ rst have been described by 
Mauthner in 1872.1 It has a prevalence of about 1:50 000, 
with northern Finland having the highest reported 
prevalence.2 Loss of night vision begins in the ﬁ rst 
decade of life and progresses with a gradual loss of 
peripheral vision and legal blindness by the ﬁ fth decade. 
Choroideremia is caused by mutations in the CHM 
gene, which was one of the ﬁ rst genes identiﬁ ed by use 
of positional cloning.3,4 Subsequently, prenylation 
deﬁ ciency due to absence of Rab escort protein-1 (REP1) 
encoded by CHM was identiﬁ ed as the cause of retinal 
degeneration in choroideremia.5 Nearly all reported 
cases of choroideremia so far have been attributed to 
functionally null mutations that, combined with the 
slow rate of degeneration and small size of the CHM 
protein coding sequence (1·9 kb), make gene therapy 
with adeno-associated viral (AAV) vectors an appealing 
treatment strategy.
In patients with choroideremia, generally good visual 
acuity is maintained until the degeneration encroaches 
on the fovea; however, underlying changes in the retina 
can be identiﬁ ed in childhood and are associated with 
clinically signiﬁ cant reductions in parafoveal retinal 
sensitivity as measured with psychophysical testing.6 
Therefore, before the onset of loss in visual acuity, retinal 
sensitivity might be a useful indicator of the functional 
eﬀ ects of gene therapy in patients with choroideremia. 
Furthermore, in a phase 1 clinical trial to assess the eﬀ ects 
of an intravitreal ciliary neurotrophic factor implant, one 
of the ten patients enrolled had choroideremia and this 
patient was noted to have an improvement of 13 letters 
(over two lines) in visual acuity 24 weeks after the 
implantation.7 Hence, the few data available so far suggest 
that loss of visual acuity might have a reversible 
component in the later stages of the disease. Although 
improvements in visual function provide a useful early 
marker of successful gene transfer, ultimately any genetic 
treatment should be aimed at halting or at least 
signiﬁ cantly slowing the rate of degeneration.
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Figure 1: Retinal detachment 
in patients’ eyes exposed to 
vector
Images show the retina in 
patients 1–6 (A, D, G, J, M, and 
P, respectively) and the 
corresponding baseline 
autoﬂ uorescent retina (B, E, H, 
K, N, and Q, respectively). The 
area of autoﬂ uorescent retinal 
pigment epithelium exposed 
to vector is annotated on each 
panel in mm². The limits of the 
retinal detachment are 
indicated by the green dotted 
line and the injection site is 
indicated with a green dot. 
The corresponding 
autoﬂ uorescence images and 
measurements in the retinal 
pigment epithelium at 
6 months are shown in panels 
C, F, I, L, O, and R. The area of 
the retinal pigment epithelium 
did not change substantially 
6 months after surgery, 
although focal loss of 
autoﬂ uorescence superior to 
the injection site was noted in 
patient 3 (I). In patients 4 
and 6, more than one injection 
was required to detach the 
fovea (additional green lines).
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Choroideremia derives its name from the almost 
complete loss of the retina, choroid, and retinal pigment 
epithelium that leads to exposure of the underlying white 
sclera, which is a unique feature compared with other 
retinal degenerations. Centripetal to the advancing 
degeneration, the retinal layers remain fairly intact and 
normal central retinal thickness might be maintained 
until the ﬁ fth decade.6 These anatomical features are 
relevant to gene therapy approaches because the volume 
of tissue to be targeted is continually shrinking and the 
multiplicity of infection of viral particles per cell will vary 
at diﬀ erent stages of the disease. The area of surviving 
tissue can, however, be measured with autoﬂ uorescence 
imaging, which detects ﬂ uorescent visual cycle products 
in the retinal pigment epithelium.8 Furthermore, the 
functional central retina is generally much thicker in 
choroideremia than in Leber congenital amaurosis and 
hence might be more resilient to damage from foveal 
detachment that is induced by subretinal injection.9 We 
therefore assessed AAV gene therapy in patients with 
diﬀ erent stages of choroideremia.
Methods
Patients and study design
Six male patients with a clinical phenotype of 
choroideremia and predicted null mutations in the CHM 
gene were enrolled into this multicentre trial after they 
provided written informed consent. The ages of 
patients 1–6 were 63 years, 47 years, 35 years, 55 years, 
41 years, and 56 years, respectively. The patients 
represented diﬀ erent stages of the disease against which 
to assess the eﬃ  cacy of the intervention—a normal foveal 
structure, partial foveal collapse, and complete foveal loss 
(ﬁ gure 1). The Gene Therapy Advisory Committee (UK 
Department of Health) provided ethics approval.
Vector production
The AAV2 expression cassette comprised a chicken β actin 
promoter, established for long-term transduction of the 
retinal pigment epithelium in previous clinical trials of 
human retinal gene therapy,9,10 and a Woodchuck hepatitis 
virus post-translational regulatory element (WPRE) 
downstream of the CHM cDNA (encoding REP1). WPRE 
is known to enhance AAV-mediated transgene expression,11 
and was approved by the US Food and Drug Administration 
for a clinical trial of AAV2 for Parkinson’s disease.12 This 
human REP1 sequence was previously shown in vitro to 
restore prenylation activity when delivered by an adenoviral 
vector to cells isolated from patients with choroideremia.13 
The subsequent preclinical data for the eﬀ ects of this vector 
(AAV2.REP1) in restoring prenylation activity to human 
choroideremia ﬁ broblasts and the electro retinogram in 
mouse choroideremia are described elsewhere.14 
PF68 surfactant was added to prevent non-speciﬁ c binding 
of AAV particles to plastics inside the injection system.15
Surgery
Because of the unpredictability of detachment of the 
retina in choroideremia, patients were injected with 
AAV2.REP1 as a two-step procedure. Surgery was ﬁ rst 
undertaken to detach the retina through a 41G Teﬂ on 
cannula (DORC International BV, Zuidland, 
Netherlands) using balanced salt solution (Alcon 
Laboratories, Fort Worth, TX, USA). Once the retinal 
target area had been detached from the underlying 
retinal pigment epithelium, a ﬁ xed volume (0·1 mL) 
containing 1 × 10¹⁰ genome particles of AAV2.REP1 was 
injected through a fresh syringe into the subretinal 
space that had been created in the ﬁ rst ﬁ ve patients. In 
patient 6, a reduced dose of up to 6 × 10⁹ genome 
particles was injected. The vector was injected slowly 
through the same retinotomy, causing the detachment 
to extend further. Surgery was uncomplicated in the 
ﬁ rst ﬁ ve patients, but in patient 6 diﬃ  culty in 
detachment of the retina from the peripheral macula 
necessitated the induction of detachment from a point 
close to the fovea (ﬁ gure 1Q), which caused visible 
stretching of the papillomacular bundle. Because of 
concerns about stretch-related damage of this vital 
structure in a patient with 6/7·5 vision, a smaller 
volume of vector (maximum 0·06 mL) was injected in 
the second step. In all patients, the surplus vector 
remaining in the syringe was expelled through the 
cannula into a polypropylene vial and then frozen. This 
surplus vector was later tested for potency with western 
blot after transduction of the human-derived 
HT1080 cell line (appendix). Patients were treated with 
a 10-day oral course of prednisolone, starting 2 days 
See Online for appendix
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Mean (SE)
Change in treated eye visual acuity (ETDRS) +21 –1 –3 +11 –2 –3 +3·8 (4·1)
Change in control eye visual acuity (ETDRS) +11 –3 +4 –1 0 –2 +1·5 (2·1)
Change in maximal sensitivity (dB) +5 +2 +4 0 +2 +1 +2·3 (0·8)
Change in mean sensitivity (dB) +4·4 +0·6 +2·0 +4·5 +1·1 –2·3 +1·7 (1·0)
Change in control eye mean sensitivity (dB) –2·3 –3·1 +2·2 –4·1 –1·1 –1·2 –1·6 (0·9)
Area of retina treated with vector (mm²) 0·76 3·20 8·46 1·23 1·79 8·67 4·02 (1·48)
Dose of vector (genome particles × 10⁹ per mm2 retina) 13·2 3·1 1·2 8·1 5·6 0·7 5·3 (1·9)
ETDRS=Early Treatment for Diabetic Retinopathy Study (a standard vision test).
 Table: Changes in visual function from baseline to 6 months after gene therapy
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Figure 2: Microperimetry at 
baseline and 6-month 
follow-up in both eyes of 
patients with choroideremia 
given gene therapy
Snellen equivalents and 
microperimetry 
measurements are shown for 
both eyes. The left column 
shows measurements at 
baseline in patients 1–6 (A, C, 
E, G, I, and K, respectively) and 
the right column shows the 
results 6 months after surgery 
(B, D, F, H, J, and L, 
respectively).The eyes injected 
with vector are indicated by a 
green icosahedron. The 
stimulus points from the 
baseline measurements are 
stored in the software and 
mapped onto identical regions 
of retina during follow-up 
testing. Black dots indicate 
points not seen at 0 dB. The 
movement of the left fundus 
image in patient 1 (A, B) 
represents a real shift in 
ﬁ xation (ﬁ gure 3). The white 
arrow in panel L is adjacent to 
the site of the subretinal 
injection. Although there was 
thinning in this area, it 
become the most sensitive 
point in this retina at 26 dB 
(fovea 21 dB).
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before surgery at 1 mg/kg (70–100 mg) for 7 days and 
then reduced to 40 mg for 1 day, 20 mg for 1 day, and 
10 mg for 1 day. Blood samples were taken for 
immunological tests before, and 1 week and 5–6 weeks 
after surgery.
Clinical assessments
All patients had best corrected visual acuity and contrast 
sensitivity measured in each eye separately after a 
standardised refraction. Measurement of best corrected 
visual acuity was done in accordance with the established 
protocols of the Early Treatment for Diabetic Retinopathy 
Study16 with a masked tester. Microperimetry was done 
with a Maia system (CenterVue, Padova, Italy) in 
accordance with the manufacturer’s protocol with 20 min 
of dark adaptation (1·5 cd/m²) before testing with a 
background luminance set at 4 apostilb (equivalent 
to 1·3 cd/m²). At least three full microperimetry tests 
were done by one of two operators before they obtained 
baseline data so as to reduce any learning eﬀ ects and to 
identify accurately the regions of seeing retina around 
which the customised maps were plotted. Before the 
start of the study, CenterVue adapted the autoexposure of 
the inbuilt camera to avoid overexposure in patients with 
choroideremia.
This study is registered with ClinicalTrials.gov, number 
NCT01461213.
Role of the funding source
The Health Innovation Challenge Fund requested 
securing of background intellectual property relating to 
the vector before it provided funding for the trial. 
Milestones for funding tranches were imposed with 
regard to obtaining regulatory approvals and recruitment 
of patients. The funding source had no role in data 
gathering or interpretation, or in writing of the report. 
The corresponding author had full access to all the data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication.
Results
The study started on Oct 20, 2012, and is ongoing. The 
residual retina overlying the area of autoﬂ uorescence was 
detached in all six patients and the limits of detachment 
(vector exposure) are shown in ﬁ gure 1. The size range of 
Figure 3: Detailed analysis of retinal function and structure in patients with 
choroideremia
(A) Pre-surgery and (B) 6 months post-surgery analysis of patient 1 showing a 
shift in the cloud of variable ﬁ xation (blue dots; B, white arrow) into the area of 
retina exposed to vector (dotted white line), but away from the area of surviving 
autoﬂ uorescent retinal pigment epithelium (white solid line) that was not 
exposed to vector. The increase in retinal sensitivity also correlated anatomically 
with the region of surviving retina exposed to AAV.REP1 (C, dotted line) and 
residual outer retina identiﬁ ed with optical coherence tomography scanning 
(D, green arrow). The thin fovea and injection site can be seen on either side of 
the residual retina (green arrow). Green dot (L) is the mean centre of all ﬁ xation 
points. ETDRS=Early Treatment for Diabetic Retinopathy Study (a standard 
vision test). AAV=adeno-associated virus. REP1=Rab escort protein 1.
ETDRS 23 lettersA
ETDRS 44 letters
L
L
B
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200 µm
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the target area in the surviving retina that was exposed to 
vector was greater than 1 log unit, from 0·76 mm² to 
8·67 mm² (ﬁ gure 1; table).
The six patients had a mean gain in visual acuity in 
their treated eyes of 3·8 letters (SE 4·1), but this value 
masked two distinct emerging patterns in the group 
(table). Patients 1 and 4, in whom visual acuity 
was reduced at baseline, gained 21 letters and 11 letters, 
respectively, whereas the other four patients with baseline 
visual acuity better than 6/9 had a marginal loss of 
one to three letters by 6 months (table). Both 
patients 1 and 4 reported subjective improvements in 
vision in their treated eyes (appendix p 13) that were 
consistent with the gains in their visual acuity. Since the 
measured gains in visual acuity in these two patients 
were substantial (table), additional veriﬁ cation was 
obtained with the patients’ permission from their regular 
optometrists. These additional independent records, 
with data from at least the past 4 years, were used to 
conﬁ rm the baseline measurements and subsequent 
gains in visual acuity after gene therapy in patients 1 and 4 
(appendix p 13).
The point of maximal sensitivity represents the 
minimal detectable light stimulus and is therefore more 
relevant than visual acuity to rod photoreceptor function 
in patients who have been adapted to mesopic light 
levels. It increased by a mean of 2·3 dB (95% CI 0·8–3·8) 
in the treated eyes from 23·0 dB (SE 1·1) at baseline 
to 25·3 dB (1·3) 6 months after surgery, reaching 28 dB 
(which is within the normal population range) in two of 
the treated eyes. Mean retinal sensitivity 
increased by 2·5 dB (1·1) in the ﬁ ve eyes administered 
the full dose of vector, but fell by 2·3 dB in the eye 
administered the reduced dose, which also had the 
largest target area (ﬁ gure 2; table). A similar non-
signiﬁ cant increase was seen for the changes in visual 
ﬁ eld sizes in these eyes (appendix p 12).
As a subjective visual assessment, microperimetry is 
subject to concentration and learning eﬀ ects and possibly 
seasonal eﬀ ects when tests are done 6 months apart.17 
Hence, microperimetry measurements for the treated 
eyes were compared with those for the untreated eyes, 
which also provided a control for the natural course of 
the degeneration (table; appendix p 12). At 6-month 
follow-up, mean reduction in retinal sensitivity was 
noted in the unoperated control eyes with respect to the 
dimmest stimulus seen (–0·8 dB [SE 1·5]), mean retinal 
sensitivity (–1·6 dB [0·9]), and total number of test points 
seen (–1·3 [1·4]). Conversely, 6 months after gene therapy, 
a mean increase was noted in retinal sensitivity in the 
treated eyes with respect to the dimmest stimulus seen 
(2·3 dB [0·8]), mean retinal sensitivity (1·7 dB [1·0]), and 
total number of test points seen (1·5 [2·3]). Although 
these measurements were not independently signiﬁ cant 
(p>0·05), the overall trend is in keeping with a slow 
degeneration in the control eyes, against a treatment 
eﬀ ect from gene therapy in the eyes undergoing retinal 
detachment by 6 months (table; appendix pp 11–12).
Further analysis of the visual function in 
patient 1 at 6 months showed that his ﬁ xation points had 
moved towards the region exposed to the vector (ﬁ gure 3). 
Before surgery he had lost foveal ﬁ xation and his 
Figure 4: Vector doses administered to and vision changes in patients with choroideremia
(A) Western blot showing REP1 expression from aliquots of 1:10 residual diluted vectors that were removed from 
syringes after administration to patients and applied to a human cell line (HT1080) in culture. Also shown are the 
positive (hREP1) and negative controls (lysate from non-transduced cells) and the loading control (α tubulin). 
(B) Changes in best corrected visual acuity in ETDRS letters in each of the six patients. Horizontal lines represent 
baseline levels and the columns represent changes at 6 months in the treated (green) and fellow eyes (blue). 
(C) Shows the changes in retinal sensitivity measured with microperimetry before and 6 months after surgery in the 
treated and control eyes. The improvement in the treated eyes was correlated with the dose of vector genome 
particles per mm² in the surviving retina. hREP1=human Rab escort protein 1 (tagged protein positive control). 
REP1=Rab escort protein 1. ETDRS=Early Treatment for Diabetic Retinopathy Study (a standard vision test). 
AAV=adeno-associated virus. *Patients 1 and 4 with the greatest improvement in retinal sensitivity also had notable 
improvements in visual acuity.
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preferred retinal locus was variable, but mainly in the 
region just below where the fovea previously existed 
(ﬁ gure 3A). By 6 months after gene therapy, his preferred 
retinal locus, although still variable, had shifted towards, 
and at times incorporated, the residual area of 
autoﬂ uorescence exposed to vector (ﬁ gure 3B; appendix 
p 21). Importantly, this shift in ﬁ xation bypassed a closer 
island of autoﬂ uorescence that had not been exposed to 
the vector (ﬁ gure 3C, D). The ﬁ ve other patients 
maintained foveal ﬁ xation throughout, and this ﬁ xation 
correlated with the point of maximal sensitivity measured 
with microperimetry in patients 2–5 (ﬁ gure 2). In 
patient 6, however, the point of maximal sensitivity 
moved superonasally away from the fovea to the region 
adjacent to where the vector had been injected (ﬁ gure 2L, 
location indicated by arrow).
In choroideremia, the area of residual auto ﬂ uorescence 
in the retinal pigment epithelium is broadly 
representative of the amount of remaining tissue that 
needs to be targeted by gene therapy.8 This area varied 
over 1 log unit in our patients and the amount of vector 
administered diﬀ ered between patients 1–5 and 
patient 6. Furthermore, the vector had been stored for 
diﬀ erent periods and diluted 1:10 before administration 
in the operating theatre. Hence, to assess any treatment 
eﬀ ect, the potency of the vector administered to each 
patient was compared. The dose was then calculated 
relative to the area of target tissue into which the vector 
would be absorbed from the subretinal space. A western 
blot of the proteins from HT1080 cells transduced with 
the unused surplus vector remaining from 
administration from each patient showed broadly 
similar levels of protein expression (ﬁ gure 4A). The 
increase in mean retinal sensitivity was correlated with 
the dose administered per unit area (log genome 
particles per mm² retina) to the treated eyes (r=0·82, 
p=0·04; ﬁ gure 4C). No correlation was noted in the 
untreated eyes, which showed the opposite trend 
(r=–0·59, p=0·21; ﬁ gure 4C), in keeping with the slow 
progression of the disease in the later stages.
Since retinal thinning after subfoveal gene delivery has 
been a concern in other gene therapy trials,9 the thickness 
of the outer retina was measured in each patient before 
and 6 months after surgery. Because the fovea could not 
be identiﬁ ed clearly in patients 1 and 4, the thickest region 
of the retina was chosen. The mean thickness of the retina 
in the six patients was similar before and 6 months after 
surgery at 175 μm (SE 27) and 169 μm (26), respectively. 
Notable outer retinal thinning was seen only in patient 6 in 
a non-seeing area just nasal to the fovea (appendix p 16), 
which corresponded to the region that stretched during 
subretinal injection. There was no clinically signiﬁ cant 
loss of visual acuity in this patient. In the six patients, the 
mean area of surviving retina, as measured with 
autoﬂ uorescence, was similar at baseline and 6 months 
after surgery (4·0 mm² [1·8] and 3·9 mm² [1·7], 
respectively; ﬁ gure 1).
Discussion
After subretinal administration of the AAV.REP1, the two 
patients with the most advanced choroideremia had 
substantial gains in visual acuity (panel). The other four 
patients with near-normal visual acuity at baseline 
received subretinal vector without any signiﬁ cant 
detrimental eﬀ ects. In the cohort, we noted an 
improvement in maximal retinal sensitivity in the eyes 
treated with AAV.REP1, despite detachment of the macula, 
which is usually associated with a reduction in retinal 
sensitivity. The ﬁ ve patients who received the full dose of 
AAV vector had improvements in mean retinal sensitivity 
in their detached retinas 6 months after surgery.
A notable diﬀ erence compared with other retinal 
degenerations is that all target tissue layers 
(photoreceptors, retinal pigment epithelium, and choroid) 
are continually shrinking in choroideremia. Since 
subretinal ﬂ uid is taken up largely through the retinal 
pigment epithelium and into the choroid rather than 
across bare sclera, it is likely that the multiplicity of 
infection per cell in the retinal pigment epithelium will 
increase for a ﬁ xed titre of vector as the target area shrinks 
in size. Hence, comparison of the dose per mm2 of target 
tissue might be advantageous, and was correlated with 
the treatment eﬀ ect. An alternative explanation for the 
apparent dose eﬀ ect, however, might be that the smaller 
areas have more advanced disease in which the capacity 
for functional improvement might be greater.
Previous reports of retinal gene therapy have shown 
long-term beneﬁ cial eﬀ ects on visual function in patients 
with Leber congenital amaurosis,8,18 including treatment 
of their second eyes.19 Although assessment with 
microperimetry is subjective, the results were consistent 
in the patients in our study in whom the most signiﬁ cant 
improvements were also accompanied by measurable 
gains in best corrected visual acuity, which was an 
independent test. In our cohort, only one patient had 
complete loss of foveal ﬁ xation before surgery. Although 
still variable, by 6 months his ﬁ xation had shifted to 
include the small residual island of retina ectopic to the 
Panel: Research in context
Systematic review
We searched PubMed for all publications, including clinical trial reports and reviews, 
with the terms “retina”, “gene therapy”, “choroideremia” (or “choroideraemia”), and 
“retinitis pigmentosa”, and found reports of gene therapy used to target the retinal 
pigment epithelium in patients with Leber congenital amaurosis due to deﬁ ciencies in 
the RPE65 gene.
Interpretation
To our knowledge, this study is the ﬁ rst assessment of retinal gene therapy administered to 
patients who have normal visual acuity. It is also the ﬁ rst report of targeting a gene 
expressed in the photoreceptors. The results show the potential for gene therapy, not just 
in the treatment of choroideremia, but also for other chronic retinal degenerations that 
require early intervention before the onset of visual loss. These retinal degenerative diseases 
include retinitis pigmentosa and age-related macular degeneration.
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fovea that had been exposed to vector. This ﬁ nding is 
noteworthy because the ﬁ xation shift bypassed a closer 
island of residual retina that was not exposed to vector, 
and it is diﬃ  cult to explain how a patient might change 
his ﬁ xation in this way if the sensitivity of the island 
exposed to vector had not improved by a clinically 
signiﬁ cant amount. This ﬁ xation shift is similar to that 
reported in a patient with RPE65 mutations treated with 
vector that was ectopic to the fovea.20 This patient also 
had a slight improvement in visual acuity in his control 
eye, equivalent to about one line in the Snellen test. 
Although this outcome most likely represents inter-test 
variability, improvements in control eyes with low vision 
have been noted after gene therapy in some patients with 
Leber congenital amaurosis, possibly due to reduced 
nystagmus.19 By contrast, the microperimetry measure-
ments deteriorated in the control eye of this patient, but 
the test was done under mesopic conditions and 
therefore included measurement of rod function, 
whereas visual acuity measurements were done in bright 
scotopic conditions. Hence, microperimetry and visual 
acuity tests to some extent provide complementary 
information about rod and cone function.
The results of a recent report have suggested that 
retinal degeneration continues in some patients with 
RPE65 mutations despite successful gene transfer.18 It is 
important to note, however, that the neurosensory retina 
and retinal pigment epithelium had advanced disease 
and degeneration at the time of intervention in patients 
and might have been beyond the point of recovery. By 
contrast, the goal in treatment of choroideremia would 
be to intervene while the retinal architecture remains 
fairly well preserved. Furthermore, phase 1 data from the 
RPE65 gene therapy trials should not be overinterpreted—
the continued degeneration might simply reﬂ ect a 
requirement for a higher vector dose than that 
administered. In our study, there were no obvious 
detrimental eﬀ ects from detachment and treatment of 
the fovea. Although there will undoubtedly be some 
damage to photoreceptors as a result of retinal 
detachment, it was not clinically signiﬁ cant in our 
patients and anatomical evidence of thinning was only 
seen in one of six cases. Foveal thinning including 
macular hole formation has, however, been noted after 
subfoveal gene therapy in several patients in the 
RPE65 gene therapy trials.9 This outcome might be 
explained partly by the fairly thick foveal tissue in patients 
with choroideremia compared with the thin surrounding 
degenerate retina and might (according to Hooke’s law) 
undergo proportionately less horizontal stretch during 
the subretinal injection. The lack of thinning of the 
central retina in the early years of choroideremia might 
also provide the opportunity for gene therapy to slow or 
possibly even stop the ensuing degeneration, as predicted 
in the early stages of Leber congenital amaurosis.18
Since CHM is expressed ubiquitously, a key question in 
gene therapy for patients with choroideremia is to decide 
which retinal layer to target with the vector. Regeneration 
of choroidal vessels has been reported in patients with 
this disease,21 suggesting that the choroidal vasculature 
has no intrinsic dependence on REP1. Hence, the 
choroidal atrophy could all be secondary to loss of the 
overlying retinal pigment epithelium, as occurs in 
dominantly inherited mutations in RPE65, which result 
in a phenotype similar to choroideremia.22 Although 
photoreceptors will degenerate secondary to the loss of 
retinal pigment epithelium, we have previously noted in 
the mouse model of choroideremia that rod 
photoreceptors might also degenerate independently.23 
Hence, AAV2 was chosen for this gene therapy trial 
because it is known to be safe for use in the human retina 
and has good tropism for primate retinal pigment 
epithelium and to some extent rod photoreceptors.24 The 
chicken β actin promoter also has long-term proven 
eﬃ  cacy in the previous RPE65 gene therapy trials,25 
including readministration to the second eye.19 
Choroideremia results almost exclusively from 
functionally null mutations,4,26 which has the additional 
advantage that transgenic mRNA will in most cases not 
be in competition with mutant mRNA27 and might make 
gene therapy dosing more predictable than in other 
genetic diseases. To our knowledge, our report is the ﬁ rst 
in which the eﬀ ects of retinal gene therapy in patients 
with good visual acuity of 6/6 or better and before the 
onset of clinically signiﬁ cant retinal thinning are 
described. These ﬁ ndings support the development and 
use of gene therapy to prevent loss of sight in other retinal 
diseases, such as age-related macular degeneration.
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